Markets India

Sai Life Sciences’ share price jumped 10.3% to ₹1,775, its highest level on the NSE, driven by a 23% revenue surge and 17% profit growth in Q2 FY27.

Sai Life Sciences Surges 10.3% to Record High on Q2 Earnings Growth

Sai Life Sciences reported Q2 FY27 earnings showing revenue of ₹659 crore, up 23% year-on-year, and profit after tax of ₹98 crore, a 17% increase. The company also announced ₹621 crore in capacity expansion investments in H1 FY27. EBITDA margins reached 28% for the quarter, while average trading volume spiked over 10-fold, with 3.4 million shares traded on the NSE and BSE. PL Capital forecasts revenue, EBITDA, and PAT CAGR of 21%, 25%, and 26% respectively over FY26–29E. The stock’s rally reflects confidence in its integrated outsourcing model and growth trajectory, though reliance on large-pharma clients remains a key risk.

The earnings growth and expansion plans underscore Sai Life’s position as a leading CRDMO in India, enhancing its ability to secure long-term contracts. Management highlighted progress in its development and commercial pipeline, alongside planned capex of ₹1,100–1,300 crore for FY27E. Analysts note the company’s strong process chemistry expertise is driving adoption of CRDMO services, while existing customers are increasing their wallet share.

Investors, customers, and partners benefit from the company’s expanded capabilities and outsourcing model. However, risks include dependency on large-pharma engagements and potential delays in expansion projects. PL Capital’s target price of ₹1,620 remains above the current share price, signaling continued optimism despite market volatility.

The company’s strategic focus on capacity expansion and customer relationships positions it for sustained growth, though balancing large-pharma reliance with diversified opportunities will be critical.

Management reiterated expectations for a stronger second half, with continued progress on capacity expansion and customer relationships. PL Capital’s target price of ₹1,620 remains above the current share price.

Sai Life’s strong Q2 results and expansion drive confidence, but reliance on large-pharma clients introduces key risk.

Topics: Biotechnology, Pharmaceuticals, CRDMO, India Markets, Financial Results, Share Price, Earnings Growth, Outsourcing Model, Investment Analysis

#SaiLifeSciences #CRDMOExpansion #IndiaBiotech #PharmaceuticalOutsourcing #EarningsGrowth #SharePriceSurge

Source: Business Standard